Related Experiment Video
Updated: Oct 3, 2025

Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
Towards Structure-Guided Development of Pain Therapeutics Targeting Voltage-Gated Sodium Channels
Phuong T Nguyen1, Vladimir Yarov-Yarovoy1,2
1Department of Physiology and Membrane Biology, University of California, Davis, Davis, CA, United States.
Abstract:
Voltage-gated sodium (NaV) channels are critical molecular determinants of action potential generation and propagation in excitable cells. Normal NaV channel function disruption can affect physiological neuronal signaling and lead to increased sensitivity to pain, congenital indifference to pain, uncoordinated movement, seizures, or paralysis. Human genetic studies have identified human NaV1.7 (hNaV1.7), hNaV1.8, and hNaV1.9 channel subtypes as crucial players in pain signaling. The premise that subtype selective NaV inhibitors can reduce pain has been reinforced through intensive target validation and therapeutic development efforts. However, an ideal therapeutic has yet to emerge. This review is focused on recent progress, current challenges, and future opportunities to develop NaV channel targeting small molecules and peptides as non-addictive therapeutics to treat pain.
Related Concept Videos
Analgesia and Pain Management
Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
Non-gated Ion Channels
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
Mechanically-gated Ion Channels
Pain
Local Anesthetics: Differential Sensitivity of Nerve Fibers

